Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of hydrophilic beta-lactam antibiotics in critically ill patients with dynamic renal dysfunction
ChiCTR1900022434Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of meropenem, imipenem and piperacillin + tazobactam in Infection (2 cohorts), sponsored by Ruijin Hospital. Primary endpoint: Targeted pharmacokinetic attainment. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
meropenemimipenempiperacillin + tazobactam
03
Conditions
Infection
Beyond the preview
Go deeper on ChiCTR1900022434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022434.